Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPOZA: Pirtobrutinib in CLL After Zanubrutinib
NCT06812715Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- May 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Clonal dynamics of BTK mutations in CLL up to 36 months. Started May 2025; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06812715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812715.